A method of treating or inhibiting the symptoms of acute respiratory distress syndrome, especially that associated with Covid-19, said method comprising administering an effective amount of a cytokine and/or innate immune response modulating natural extract, its components or metabolites, or combinations thereof capable of modulating those cytokine and/or innate immune response associated mechanisms associated with acute respiratory distress.

An adipocyte-targeting DNA nanodrug, and preparation and uses thereof. The drug is composed of an adipocyte-targeting DNA microstructure and tannic acid (TA) in a weight ratio of 1:25-30. Among them, the small molecular antioxidant TA is loaded into the DNA microstructure. The DNA microstructure incorporated with an adipocyte-targeting aptamer sequence can specifically recognize and bind with adipocytes. TA and DNA microstructure can interact with each other through multiple hydrogen bonds to form the adipocyte-targeting, safe and efficient DNA nanodrug.

An adipocyte-targeting DNA nanodrug, and preparation and uses thereof. The drug is composed of an adipocyte-targeting DNA microstructure and tannic acid (TA) in a weight ratio of 1:25-30. Among them, the small molecular antioxidant TA is loaded into the DNA microstructure. The DNA microstructure incorporated with an adipocyte-targeting aptamer sequence can specifically recognize and bind with adipocytes. TA and DNA microstructure can interact with each other through multiple hydrogen bonds to form the adipocyte-targeting, safe and efficient DNA nanodrug.

The invention provides methods and compositions for the inhibition of fucosylation of proteins, including antibodies, in vivo by administration of a fucose analog.

The invention provides methods and compositions for the inhibition of fucosylation of proteins, including antibodies, in vivo by administration of a fucose analog.

The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ALD). More specifically the present embodiments relate to the prevention and treatment of ALD through the administration of an Retinoic Acid Receptor (RAR) agonist. Some embodiments relate to use of tazarotene in the prevention and treatment of alcohol-induced liver injury, alcohol-related liver disease, fatty liver disease, hepatic steatosis, alcoholic hepatitis or alcoholic cirrhosis.

The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ALD). More specifically the present embodiments relate to the prevention and treatment of ALD through the administration of an Retinoic Acid Receptor (RAR) agonist. Some embodiments relate to use of tazarotene in the prevention and treatment of alcohol-induced liver injury, alcohol-related liver disease, fatty liver disease, hepatic steatosis, alcoholic hepatitis or alcoholic cirrhosis.

A method of treating cancer is provided wherein the method comprises inhibiting or reducing sialylation of specifically Mesenchymal Stromal Cells (MSCs) to inhibit MSC immunosuppression and restore T cell proliferation in cancer. The method may comprise administering a sialyltransferase inhibitor (e.g. 3Fax-Peracetyl Neu5Ac) or sialidase. Also described is administration of MSCs which have been manipulated prior to administration to remove sialic acids and use of a small molecule or blocking antibody which blocks interactions between MSC-sialic acid and lectins, such as Siglec 7, and/or blocks interactions between MSC-lectins and sialic acid.

A method of treating cancer is provided wherein the method comprises inhibiting or reducing sialylation of specifically Mesenchymal Stromal Cells (MSCs) to inhibit MSC immunosuppression and restore T cell proliferation in cancer. The method may comprise administering a sialyltransferase inhibitor (e.g. 3Fax-Peracetyl Neu5Ac) or sialidase. Also described is administration of MSCs which have been manipulated prior to administration to remove sialic acids and use of a small molecule or blocking antibody which blocks interactions between MSC-sialic acid and lectins, such as Siglec 7, and/or blocks interactions between MSC-lectins and sialic acid.

The invention relates to brartemicin analogues of Formula (IV) and their uses. These compounds are potent Mincle agonists and Th1-stimulating vaccine adjuvants.

##STR00001##